Takeda reported top-line Phase 3 results for zasocitinib (TAK-279), positioning the oral TYK2 inhibitor as statistically superior to Bristol Myers Squibb’s Sotyktu (deucravacitinib) in a head-to-head plaque psoriasis trial readout. The announcement strengthens Takeda’s late-stage strategy in inflammatory disease by targeting the same pathway with a distinct pharmacology profile. The Phase 3 update also feeds ongoing market competition for oral, selective TYK2 therapeutics, where differentiation hinges on depth and speed of response as well as durability and safety. If Takeda follows with regulatory filings as planned, the data could shift treatment preferences toward a second-generation oral TYK2 option.